Literature DB >> 22388630

Rationale for the use of radiolabelled peptides in diagnosis and therapy.

K P Koopmans1, A W J M Glaudemans.   

Abstract

Nuclear medicine techniques are becoming more important in imaging oncological and infectious diseases. For metabolic imaging of these diseases, antibody and peptide imaging are currently used. In recent years peptide imaging has become important, therefore the rationale for the use of peptide imaging is described in this article. Criteria for a successful peptide tracer are a high target specificity, a high binding affinity, a long metabolic stability and a high target-to-background ratio. Tracer internalization is also beneficial. For oncological imaging, many tracers are available, most originating from regulatory peptides, but penetrating peptides are also being developed. Peptides for imaging inflammatory and infectious diseases include regulatory peptides, antimicrobial peptides and others. In conclusion, for the imaging of oncological, imflammatory and infectious diseases, many promising peptides are being developed. The ideal peptide probe is characterized by rapid and specific target localization and binding with a high tumour-to-background ratio.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388630     DOI: 10.1007/s00259-011-2038-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  8 in total

Review 1.  Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.

Authors:  Yu-Ping Xu; Min Yang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

2.  Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate.

Authors:  Mila V Todorović-Tirnanić; Milan M Gajić; Vladimir B Obradović; Richard P Baum
Journal:  Cancer Biother Radiopharm       Date:  2014-01-22       Impact factor: 3.099

3.  Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography.

Authors:  Xiang-Guo Li; Kerttuli Helariutta; Anne Roivainen; Sirpa Jalkanen; Juhani Knuuti; Anu J Airaksinen
Journal:  Nat Protoc       Date:  2013-12-19       Impact factor: 13.491

4.  Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.

Authors:  Yuping Xu; Donghui Pan; Chen Zhu; Qing Xu; Lizhen Wang; Fei Chen; Runlin Yang; Shineng Luo; Min Yang; Yongjun Yan
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

Review 5.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

6.  Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.

Authors:  Maximilian Klingler; Christine Rangger; Dominik Summer; Piriya Kaeopookum; Clemens Decristoforo; Elisabeth von Guggenberg
Journal:  Pharmaceuticals (Basel)       Date:  2019-01-15

Review 7.  Design and applications of bispecific heterodimers: molecular imaging and beyond.

Authors:  Haiming Luo; Hao Hong; Sarah P Yang; Weibo Cai
Journal:  Mol Pharm       Date:  2014-04-28       Impact factor: 4.939

Review 8.  Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors.

Authors:  Ji Hoon Jung; Byeong Cheol Ahn
Journal:  Brain Tumor Res Treat       Date:  2018-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.